Chinese biotech investors struggle to access timely, reliable half-year financial reports for trading decisions

Chinese retail and institutional investors trading biotech stocks like Wuxi Biologics (300357) need accurate, current financial reports to make informed investment decisions, but face delays in report availability and difficulty interpreting complex financial data. Current solutions rely on fragmented sources across multiple financial websites, creating information gaps that lead to missed trading opportunities or poor investment timing.